Sepsis Diagnostics Market Worth $1,226.52 Million, Globally, by 2028 at 9.2% CAG… – Press Release

New York, May 13, 2022 (GLOBE NEWSWIRE) — The Insight Partners published latest research study on “Sepsis Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product (Instruments, Reagents and Assays, Blood Culture Media, and Software), Technology [Molecular Diagnostics (Polymerase Chain Reaction, Peptide Nucleic Acid-Fluorescent in Situ Hybridization, Syndromic Panel-Based Testing, and Microarray), Flow Cytometry, Microfluidics, Immunoassay, Biomarker, and Microbiology], Method (Automated Diagnostics and Conventional Diagnostics), Test Type (Point-of-Care Tests and Laboratory Tests), Pathogen (Bacterial Sepsis, Fungal Sepsis, and Others), and End User (Hospitals, Pathology and Reference Laboratories, and Others)”.

The Sample Pages Showcases Content Structure and Nature of Information Included in This Research Study Which Presents A Qualitative and Quantitative Analysis:

Report Coverage Details
Market Size Value in US$ 661.83 million in 2021
Market Size Value by US$ 1,226.52 million by 2028
Growth rate CAGR of 9.2% from 2021 to 2028.
Forecast Period 2021- 2028
Base Year 2021
No. of Pages 267
No. Tables 191
No. of Charts & Figures 95
Historical data available Yes
Segments covered Product, Technology, Method, Test Type, Pathogen, and End User
Regional scope North America; Europe; Asia Pacific; Latin America; MEA
Country scope US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina
Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Sepsis Diagnostics Market: Competitive Landscape and Key Developments
Abbott; F. HOFFMANN-LA ROCHE LTD.; Immunexoress, Inc.; BD; Danaher (Beckman Coulter); Luminex Corporation; Thermo Fischer Scientific Inc.; bioMerieux Inc.; T2 Biosystems, Inc.; and Axis-Shield Diagnostics Ltd are among the key companies operating in…